Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham joins Proactive in the virtual studio to highlight data from an independent third-party research organisation, which revealed the company’s lead drug candidate R327 reduces COVID-19 viral cells by up to 99.9% in an animal model. Recce is also pursuing clinical trials for treatments addressing sepsis, burn wounds, UTIs and diabetic ulcers.
Recce Pharmaceuticals achieves 99.9% viral cell reduction in R327 covid study
